[(1S,2R)-2-hydroxy-3-[(2-methylpropan-2-yl)oxy]-3-oxo-1-phenylpropyl]carbamic acid

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: [(1S,2R)-2-hydroxy-3-[(2-methylpropan-2-yl)oxy]-3-oxo-1-phenylpropyl]carbamic acid
• 化学式: C₁₄H₁₉NO₅
• 分子量: 281.3
• InChiKey: ICBJPNRJVTUWOE-WDEREUQCSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  20
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  95.9
• 氢给体数：
  3
• 氢受体数：
  5

文献信息

• NON-AQUEOUS TAXANE NANODISPERSION FORMULATIONS AND METHODS OF USING THE SAME
  申请人：Teikoku Pharma USA, Inc.

  公开号：EP2903435A1

  公开（公告）日：2015-08-12
• NON-AQUEOUS TAXANE FORMULATIONS AND METHODS OF USING THE SAME
  申请人：Teikoku Pharma USA, Inc.

  公开号：US20150094361A1

  公开（公告）日：2015-04-02

  Non-aqueous, ethanol-free taxane formulations are provided. Formulations of embodiments of the invention include a taxane, an oil, a non-ionic surfactant, a non-aqueous solvent, and an organic acid component, wherein the organic acid component is soluble in the non-aqueous solvent and the amount by weight of non-ionic surfactant is equal to or greater than the amount by weight of non-aqueous solvent. Also provided are methods of using the formulations, as well as kits that include the formulations. Non-aqueous, ethanol-free docetaxel formulations are provided. Formulations of embodiments of the invention include docetaxel, an oil, a non-ionic surfactant, a non-aqueous solvent, and an organic acid which is soluble in the non-aqueous solvent and is substantially free of any conjugate base. Also provided are methods of using the formulations, as well as kits that include the formulations.
• US9308195B2
  申请人：——

  公开号：US9308195B2

  公开（公告）日：2016-04-12
• US9763880B2
  申请人：——

  公开号：US9763880B2

  公开（公告）日：2017-09-19
• [EN] NON-AQUEOUS TAXANE NANODISPERSION FORMULATIONS AND METHODS OF USING THE SAME<br/>[FR] FORMULATIONS DE NANODISPERSION NON AQUEUSE DE TAXANE ET PROCÉDÉS D'UTILISATION
  申请人：TEIKOKU PHARMA USA INC

  公开号：WO2014055426A1

  公开（公告）日：2014-04-10

  Non-aqueous, ethanol-free taxane nanodispersion formulations are provided. Nanodispersion formulations of embodiments of the invention include a taxane, an oil, a non-ionic surfactant, a non-aqueous solvent, and an organic acid component, wherein the organic acid component is soluble in the non-aqueous solvent and the amount by weight of non-ionic surfactant is equal to or greater than the amount by weight of non-aqueous solvent. Alos provided are non-aqueous, ethanol-free docetaxel nanodispersion formulations. Nanodispersion formulations of embodiments of the invention include docetaxel, an oil, a non-ionic surfactant, a non-aqueous solvent, and an organic acid which is soluble in the non-aqueous solvent and is substantially free of any conjugate base. Also provided are methods of using the nanodispersion formulations, as well as kits that include the nanodispersion formulations.